Highly Efficient Conversion of Motor Neuron-Like NSC-34 Cells into Functional Motor Neurons by Prostaglandin E
Acetylcholine
/ metabolism
Action Potentials
/ drug effects
Animals
Biomarkers
/ metabolism
Cell Differentiation
/ drug effects
Cell Line
Cell Survival
/ drug effects
Dinoprostone
/ pharmacology
Ion Channel Gating
/ drug effects
Mice
Motor Neurons
/ cytology
Neuronal Outgrowth
/ drug effects
Neurons
/ drug effects
Tetrodotoxin
/ pharmacology
Tretinoin
/ pharmacology
acetylcholine release
action potential
motor neuron
neurite outgrowth
neuronal differentiation
prostaglandin E2
voltage-gated sodium current
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
21 07 2020
21 07 2020
Historique:
received:
11
06
2020
revised:
10
07
2020
accepted:
20
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
6
3
2021
Statut:
epublish
Résumé
Motor neuron diseases are a group of progressive neurological disorders that degenerate motor neurons. The neuroblastoma × spinal cord hybrid cell line NSC-34 is widely used as an experimental model in studies of motor neuron diseases. However, the differentiation efficiency of NSC-34 cells to neurons is not always sufficient. We have found that prostaglandin E
Identifiants
pubmed: 32708195
pii: cells9071741
doi: 10.3390/cells9071741
pmc: PMC7409148
pii:
doi:
Substances chimiques
Biomarkers
0
Tetrodotoxin
4368-28-9
Tretinoin
5688UTC01R
Dinoprostone
K7Q1JQR04M
Acetylcholine
N9YNS0M02X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Pharmacol Sci. 2017 Oct;135(2):64-71
pubmed: 28966102
Cell Biol Int Rep. 1989 Dec;13(12):1023-38
pubmed: 2517595
Br J Pharmacol. 2010 Mar;159(5):1118-25
pubmed: 20136845
Neuron. 1999 Aug;23(4):659-74
pubmed: 10482234
Front Cell Neurosci. 2017 Sep 05;11:269
pubmed: 28928636
Front Physiol. 2017 Jan 20;8:3
pubmed: 28163685
Stem Cell Reports. 2019 Feb 12;12(2):201-212
pubmed: 30639213
Nat Neurosci. 2008 Feb;11(2):178-86
pubmed: 18204443
Cell Death Differ. 2017 Mar;24(3):511-522
pubmed: 28085149
Neuron. 2003 Sep 25;40(1):81-95
pubmed: 14527435
Mol Brain. 2015 Dec 01;8(1):79
pubmed: 26626025
Neurochem Int. 2013 Jun;62(8):1029-38
pubmed: 23562846
Development. 2014 Feb;141(3):491-501
pubmed: 24449832
Pharmacol Rev. 2005 Dec;57(4):397-409
pubmed: 16382098
J Neurophysiol. 2012 Jan;107(2):728-41
pubmed: 22031766
Nat Commun. 2014 Mar 13;5:3449
pubmed: 24622388
Physiol Rev. 2015 Jul;95(3):809-52
pubmed: 26109340
J Neurosci. 2003 Oct 22;23(29):9479-90
pubmed: 14573527
Science. 1992 Jun 12;256(5063):1555-60
pubmed: 1350865
Front Cell Neurosci. 2016 May 09;10:118
pubmed: 27242431
J Neurosci. 2015 Aug 19;35(33):11462-81
pubmed: 26290227
Front Cell Neurosci. 2014 Oct 09;8:293
pubmed: 25346659
FEBS Lett. 1996 Feb 26;381(1-2):93-7
pubmed: 8641447
Neurochem Int. 2018 Oct;119:132-139
pubmed: 28687401
Cells. 2020 Apr 10;9(4):
pubmed: 32290308
J Biol Chem. 2003 Nov 14;278(46):45435-44
pubmed: 12963741
Eur J Pharmacol. 2016 Oct 15;789:402-410
pubmed: 27445235
Int J Mol Med. 2018 Jan;41(1):195-201
pubmed: 29115371
J Pharmacol Sci. 2013;121(4):347-50
pubmed: 23514786
Oxid Med Cell Longev. 2020 Jan 11;2020:6101838
pubmed: 32411331
BMC Neurosci. 2012 Oct 25;13:129
pubmed: 23095258
J Pharmacol Sci. 2016 Mar;130(3):177-80
pubmed: 27032908
Sci Rep. 2015 Nov 18;5:16763
pubmed: 26577180
J Neuroendocrinol. 2011 Sep;23(9):839-48
pubmed: 21790808
Brain. 2017 Feb;140(2):370-386
pubmed: 28007986
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3393-7
pubmed: 8159758
Exp Neurol. 2015 Sep;271:122-30
pubmed: 26024861
Nat Rev Mol Cell Biol. 2015 Feb;16(2):110-23
pubmed: 25560970
Exp Mol Med. 2003 Jun 30;35(3):203-10
pubmed: 12858020
J Neurosci. 1995 Jan;15(1 Pt 2):511-9
pubmed: 7823159
J Pharmacol Exp Ther. 2000 Feb;292(2):692-7
pubmed: 10640307
Science. 2015 Jun 12;348(6240):aaa2340
pubmed: 26068857
Mol Neurobiol. 2016 Jan;53(1):695-705
pubmed: 25577170
Exp Eye Res. 2007 Nov;85(5):678-83
pubmed: 17904550
Dev Dyn. 1992 Jul;194(3):209-21
pubmed: 1467557